Comparative Affect of a Continuous Epidural Infusion of Clonidine During Labour. Prospective Double Blind Randomized Trial
Completed
Hospices Civils de Lyon
Phase 3
2007-02-01
Addition of clonidine to an epidural mixture of local anaesthetic and morphine improves
analgesia and reduces the frequency of motor blockade during epidural analgesia. several side
effects are possible mostly somnolence and hypotension. Association of continuous clonidine
infusion with low concentrations of levobupivacaïne and sufentanil was not studied during
labour. The objective of this study is to compare the effectiveness and the side effects of a
PCEA with levobupivacaïne 0,0625 % and sufentanil 0.25 microg.ml-1, without addition of
clonidine, and with addition of clonidine at a concentrations of 2 microg.ml-1.
Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block
Unknown status
Cristália Produtos Químicos Farmacêuticos Ltda.
Phase 4
2007-10-01
The purpose of this study is to determine if bupivacaine (75% levobupivacaine plus 25%
racemic bupivacaine) with vasoconstrictor is effective and safety as ropivacaine in brachial
plexus block for orthopedic surgery.
Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block
Unknown status
University of Sao Paulo
Phase 4
2007-10-01
The purpose of this study is to determine if bupivacaine (75% levobupivacaine plus 25%
racemic bupivacaine) with vasoconstrictor is effective and safety as ropivacaine in brachial
plexus block for orthopedic surgery.
Comparison of Ropivacaine and Levobupivacaine in High Thoracic Epidural Anesthesia
Completed
Centro Cardiologico Monzino
Phase 4
2003-01-01
In High Thoracic Epidural Anesthesia (HTEA) the use of a local anesthetic (LA) with low
cardiac toxicity is crucial as myocardial contractility is often already seriously impaired.
The aim of this study is to compare the efficacy, doses and side effects of ropivacaine and
levobupivacaine in patients submitted to coronary artery bypass graft with HTEA and general
anesthesia. The primary end point is the amount of LA drug required to maintain a VAS < 4
when coughing in the first 24 postoperative hours.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
